Testing alternative schedules of adjuvant immune checkpoint blockers - The need for well-designed clinical trials

Eur J Cancer. 2023 Jan:178:88-90. doi: 10.1016/j.ejca.2022.10.024. Epub 2022 Oct 31.

Authors

Gauthier Bouche¹, Ruth Langley², Hannah Rush², Mahesh Parmar², Duncan C Gilbert²

Affiliations

¹ MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom; The Anticancer Fund, Meise, Belgium. Electronic address: g.bouche@ucl.ac.uk.
² MRC Clinical Trials Unit at UCL, UCL, London, United Kingdom.

PMID: 36427393
DOI: 10.1016/j.ejca.2022.10.024

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Clinical Trials as Topic
Humans
Immune Checkpoint Inhibitors*
Immunotherapy*

Substances

Immune Checkpoint Inhibitors

Grants and funding